This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
HistoRx today announced that the Company's proprietary AQUA technology, an automated image analysis platform based on tissue-based quantitative immunofluorescence, was noted in a recent National Comprehensive Cancer Network (NCCN) Task Force Report on hormone receptor testing in breast cancer as one of the promising new strategies being developed for the measurement of ER and PgR in breast cancer tissue.
We care about your feedback. Let us know how we can improve your CancerCompass experience.